Biomaterial Database

Effect of gemfibrozil on intermediate-density lipoproteins in NIDDM patients. A retrospective study. 1992

D S Bell, and L E Wagenknecht

UI	MeSH Term	Description	Entries
D008074	Lipoproteins	Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes.	Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D003924	Diabetes Mellitus, Type 2	A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938	Hyperlipoproteinemia Type II	A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).	Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic
D012189	Retrospective Studies	Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.	Retrospective Study,Studies, Retrospective,Study, Retrospective
D015248	Gemfibrozil	A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.	Apo-Gemfibrozil,Ausgem,Bolutol,CI-719,Chem mart Gemfibrozil,DBL Gemfibrozil,Decrelip,Gemfi 1A Pharma,Gemfibrosil,Gemfibrozilo Bayvit,Gemfibrozilo Bexal,Gemfibrozilo Ur,Gemhexal,Gen-Gemfibrozil,GenRX Gemfibrozil,Healthsense Gemfibrozil,Jezil,Lipazil,Lipox Gemfi,Lipur,Litarek,Lopid,Lopid R,Novo-Gemfibrozil,Nu-Gemfibrozil,PMS-Gemfibrozil,Pilder,SBPA Gemfibrozil,Terry White Chemists Gemfibrozil,Trialmin,Apo Gemfibrozil,ApoGemfibrozil,Bayvit, Gemfibrozilo,CI 719,CI719,Gemfibrozil, GenRX,Gemfibrozil, Healthsense,Gemfibrozil, SBPA,Gen Gemfibrozil,GenGemfibrozil,Novo Gemfibrozil,Nu Gemfibrozil,NuGemfibrozil,PMS Gemfibrozil
D053419	Lipoproteins, IDL	A mixture of very-low-density lipoproteins (VLDL), particularly the triglyceride-poor VLDL, with slow diffuse electrophoretic mobilities in the beta and alpha2 regions which are similar to that of beta-lipoproteins (LDL) or alpha-lipoproteins (HDL). They can be intermediate (remnant) lipoproteins in the de-lipidation process, or remnants of mutant CHYLOMICRONS and VERY-LOW-DENSITY LIPOPROTEINS which cannot be metabolized completely as seen in FAMILIAL DYSBETALIPOPROTEINEMIA.	Broad-beta Lipoprotein,Floating beta-Lipoprotein,Intermediate Density Lipoprotein,Intermediate-Density Lipoprotein,alpha2-Very-Low-Density Lipoprotein,alpha2-Very-Low-Density Lipoproteins,beta-VLDL Lipoprotein,beta-Very-Low-Density Lipoprotein,beta-Very-Low-Density Lipoproteins,Broad-beta Lipoproteins,Floating beta-Lipoproteins,Intermediate Density Lipoproteins,Intermediate-Density Lipoproteins,Lipoprotein, IDL,Lipoproteins, Intermediate Density,alpha2-VLDL,alpha2-VLDL Lipoprotein,beta-VLDL,beta-VLDL Lipoproteins,Broad beta Lipoprotein,Broad beta Lipoproteins,Density Lipoprotein, Intermediate,Floating beta Lipoprotein,Floating beta Lipoproteins,IDL Lipoprotein,IDL Lipoproteins,Lipoprotein, Broad-beta,Lipoprotein, Intermediate Density,Lipoprotein, Intermediate-Density,Lipoprotein, alpha2-VLDL,Lipoprotein, alpha2-Very-Low-Density,Lipoprotein, beta-VLDL,Lipoprotein, beta-Very-Low-Density,Lipoproteins, Broad-beta,Lipoproteins, Intermediate-Density,Lipoproteins, alpha2-Very-Low-Density,Lipoproteins, beta-VLDL,Lipoproteins, beta-Very-Low-Density,alpha2 VLDL,alpha2 VLDL Lipoprotein,alpha2 Very Low Density Lipoprotein,alpha2 Very Low Density Lipoproteins,beta VLDL,beta VLDL Lipoprotein,beta VLDL Lipoproteins,beta Very Low Density Lipoprotein,beta Very Low Density Lipoproteins,beta-Lipoprotein, Floating,beta-Lipoproteins, Floating

Related Publications

D S Bell, and L E Wagenknecht

Influence of gemfibrozil on high-density lipoproteins.

August 1983, The American journal of cardiology,

D S Bell, and L E Wagenknecht

Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.

July 2003, The American journal of cardiology,

D S Bell, and L E Wagenknecht

Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.

January 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

D S Bell, and L E Wagenknecht

Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM.

January 1995, Diabetes,

D S Bell, and L E Wagenknecht

Characterization of unusual intermediate density lipoproteins.

February 1982, Journal of lipid research,

D S Bell, and L E Wagenknecht

Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins.

January 1992, Atherosclerosis,

D S Bell, and L E Wagenknecht

[Very low density lipoproteins and subclasses of intermediate density lipoproteins in postmenopausal women].

January 1996, Medicina,